How characterization of excipient physical and chemical properties helps build quality into drug product Dr Brian A Carlin FMC BioPolymer.

Slides:



Advertisements
Similar presentations
Producing a Pharmaceutical or Biopharmaceutical
Advertisements

Finished Pharmaceutical Product Specifications
By Timina Olive Kayaviri Supervisor : Dr. Amugune
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Experience of Pre-Qualification Program.
Chemistry, Manufacturing, and Controls (CMC) and Good Manufacturing Practices (GMPs): The Big Picture of a Long-term Commitment Elizabeth Pollina Cormier,
Pharmaceutical Nomenclature Issues and challenges Moheb M. Nasr, Ph.D. Acting Director Office of New Drug Chemistry (ONDC) OPS, CDER, FDA Advisory Committee.
Determine impurity level in relevant batches1
Pharmaceutics I Introduction 1. Pharmaceutics Pharmaceutics is the science of dosage form design. There are many chemicals with known pharmacological.
SOURCES OF PHARMACEUTICAL INFORMATION. 1-Pharmacopeias Pharmacopoeia is a book containing an official list of the drugs used in medicine together with.
Quality control of raw materials In-process control
Assessing Quality-by-Design A CMC Review Perspective
Regulatory requirements on Medicine Stability Guidelines relevant for Stability testing Sultan Ghani.
Slide 1 of 18D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Lecture – DR. SHAHNAZ USMAN Associate Professor Dept. of Pharmaceutics RAKMHSU PHARMACOPOEIAS AND OTHER OFFICIAL COMPENDIA 1.
PAT Validation Working Group Process and Analytical Validation Working Group Arthur H. Kibbe, Ph.D. Chair June 13, 2002.
Post approval changes- Variations Mercy Acquaye. Presentation Outline Introduction to Guidance Classification of changes Approval of changes Definitions.
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Slide 1 May 2008 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008 QUALITY BY DESIGN.
Excipients: Unknown Unknowns, Unforeseen Failure Modes & Criticalities
ITFG/IPAC Collaboration CMC Specifications Technical Team ITFG/IPAC TECHNICAL TEAM: CMC SPECIFICATIONS Presented by: Bo Olsson, PhD 26 April 2000 Rockville,
Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.
Excipient QbD Concepts to Enhance the Development of Robust Drug Products Priscilla S. Zawislak Global Regulatory Affairs Manager - Ashland Inc. Chair.
Good Manufacturing Practice. Good Manufacturing Practice Regulations Establishes minimum GMP for methods to be used, and the facilities or controls to.
Section 1 Introduction to Pharmacology Humans have been treating diseases with substances around them for over 4000 yrs. These “drugs’ were chosen.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Blend Uniformity - PQRI Research
1 Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July , 2008 Classification of Orally Disintegrating Tablets Frank O. Holcombe,
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
PQRI Opening Session 1 PQRI Survey of Pharmaceutical Excipient Testing and Control Strategies Used by Excipient Manufacturers, Excipient Distributors and.
TECHNICAL REQUIREMENTS FOR MINOR APPLICATIONS E MOKANTLA 3 SEPTEMBER 2013.
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
Current issues and challenges in the development of IP monographs Dr. G.N. Singh Secretary-cum-Scientific Director Indian Pharmacopoeia Commission Ghaziabad.
Formulation factors By Dr. A. S. Adebayo.
1 Suspension 1. 2  Suspension:  Suspension: A suspension is a two-phase system consisting of a finely divided solid particles dispersed in liquid, or.
Definitions. Clinical pharmacy is the branch of Pharmacy where pharmacists provide patient care that optimizes the use of medication and promotes health,
INDIAN PHARMACOPOEIA MONOGRAPH DEVELOPMENT. INDIAN PHARMACOPOEIA MONOGRAPH DEVELOPMENT Indian Pharmacopoeia Commission (IPC) Vision The IPC is committed.
HELM AG Module 3 Christa Clasen Ankara, 6./7. April 2006.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
© AL IPA/EDQM/IDMA Symposium 2007, All rights reserved The Ph. Eur. policy on impurities Dr Andrea Lodi Deputy Head, Laboratory Department, EDQM, Council.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Some Future Developments Brian Carlin, Ph.D FMC Chris Moreton, Ph.D FinnBrit Consulting IPEC-Americas FDA Seminar, October 21,
1.  Chapter 8 covers pages  Objective  Explain need for compounding  Know equipment needed for compounding  Know techniques for compounding.
FORMATION AND FUNCTIONING OF INDIAN PHARMACOPOEIA COMMISSION (IPC) By Dr G N Singh Member-Secretary.
1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances Published by US FDA’s Center for Drug Evaluation and Research June 2009.
Excipient Variability Sources, Importance and Potential Impact Chris Moreton, Ph.D Past Chair IPEC-Americas Partner – FinnBrit Consulting
1 Office of Pharmaceutical Science on Jon Clark FDA/CDER/OPS Associate Director for Policy Development.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
How characterization of excipient physical and chemical properties helps build quality into drug products How characterization of excipient physical and.
ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team ITFG/IPAC TECHNICAL TEAM: SUPPLIER QUALITY CONTROL (QUALIFICATION) Presented by: Gordon.
Substance Structure, production process and indented use Is there adequate published safety data and exposure data for this substance to meet current GRAS.
开发报批美国 FDA 的仿制药 与相关问题探讨 上海复星普适医药科技有限公司何平. 内容提要 开发仿制药的重要性和机遇 开发仿制药的重要性和机遇 开发仿制药的挑战 开发仿制药的挑战 申报仿制药的分类 申报仿制药的分类 仿制药研发团队 仿制药研发团队 仿制药的研发过程 仿制药的研发过程 QbD 在制剂开发中怎么体现.
Good Manufacturing Practice (GMP) Compliance: GMPs EXPLAINED.
OVER THE COUNTER MEDS INTRODUCTION No prescriptions are necessary and no questions need to be answered to attain these drugs OTC med use saves.
Biological Evaluation (Lecture – 9) Reference standards Joseph O. Oweta B. Pharm (MUST)
Joint FDA OGD/IPEC Americas QbD Workshop Excipient Variability: Design & Lifecycle Implications FDA OGD – Rockville Oct. 16,
Dispersed Systems. Dispersed system:  It is liquid preparations containing undissolved or immiscible drug distributed throughout a vehicle.  The substance.
Integration of Excipients into the Design of Experiments for Pharmaceutical Product and Design Space Development Chris Moreton, Ph.D. FinnBrit Consulting.
1 IPEC-Americas General Information Go to for additional informationwww.ipecamericas.org OR contact info to
BSB Biomanufacturing CHAPTER 11 GMP – Pharmaceutical Water
REGULATORY REQUIREMENTS FOR PREFORMULATION STUDIES
- Pharmaceutical Equivalence Study
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
QUALITY BY DESIGN Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008.
Quality control Lecture 1.
Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.
Pharmaceutics I Introduction 1. Pharmaceutics Pharmaceutics is the science of dosage form design. There are many chemicals with known pharmacological.
Quality by Design.
HHM 5014 NUTRACEUTICAL FORMULATION TECHNOLOGY
Quality control Lecture 1.
The European Pharmacopoeia and Pharmeuropa
Presentation transcript:

How characterization of excipient physical and chemical properties helps build quality into drug product Dr Brian A Carlin FMC BioPolymer

Excipient Excipient \Ex*cip"i*ent\, n. 1. An exceptor. [R.] 2. (Med.) An inert or slightly active substance used in preparing remedies as a vehicle or medium of administration for the medicinal agents Excipient \Ex*cip"i*ent\, n. 1. An exceptor. [R.] 2. (Med.) An inert or slightly active substance used in preparing remedies as a vehicle or medium of administration for the medicinal agents Excipient \Ex*cip"i*ent\, a. [L. excipients, -entis, p. pr. of exipere. See Except, v. t.] Taking an exception. Excipient \Ex*cip"i*ent\, a. [L. excipients, -entis, p. pr. of exipere. See Except, v. t.] Taking an exception. Exceptor \Ex*cept"or\, n. [L., a scribe.] One who takes exceptions. Exceptor \Ex*cept"or\, n. [L., a scribe.] One who takes exceptions. Does characterization of excipient physical and chemical properties help build quality into drug product?

Definition of Quality? Compliance with specifications Compliance with specifications Drug product, raw materialsDrug product, raw materials Consistency Consistency Processability, yield Processability, yield Functionality, utility Functionality, utility PATability PATability >70% perform additional functionality or processability testing >70% perform additional functionality or processability testing 76% to determine excipient suitability76% to determine excipient suitability 66% always for the excipient66% always for the excipient >50% for oral solutions.>50% for oral solutions. 87% for solid oral dosage forms.87% for solid oral dosage forms.

Quality NOT by Design? “About 25% of the time drug product manufacturers test excipient suitability for processing, using experimental (laboratory) scale batches, or pilot scale manufacturing batches. This was higher than expected.” “About 25% of the time drug product manufacturers test excipient suitability for processing, using experimental (laboratory) scale batches, or pilot scale manufacturing batches. This was higher than expected.” “An excipient's functionality can only be assessed in the context of a particular formulation and manufacturing process” RC Moreton Pharmaceutical Technology, May 2004

Functionality transcends the excipient Application dependent (why do you add it?) Application dependent (why do you add it?) Formulation dependent (effect of other ingredients) Formulation dependent (effect of other ingredients) Process dependent (application may be process- specific) Process dependent (application may be process- specific) Trade-off (competing formulation objectives) Trade-off (competing formulation objectives) Multi-functional excipients Multi-functional excipients

Diverse Materials Base Chemical Synthesis* Chemical Synthesis* Mining of Minerals Mining of Minerals Harvesting of Vegetation Harvesting of Vegetation Formulated Products Formulated Products Biotechnology Biotechnology Genetic Modification Genetic Modification Animal By-Products Animal By-Products *Often less defined than single low mol wt entities

Pharmacopoeial compliance of limited relevance Primarily safety and purity focused Primarily safety and purity focused Mainly chemical with some limited physical characterisation Mainly chemical with some limited physical characterisation Functionality Related Characteristics (FRCs) in European Pharmacopoeia Functionality Related Characteristics (FRCs) in European Pharmacopoeia IPEC opposed to inclusion of functionality in monographs but supportive of USP proposal for general chapters on Compactability, Lubrication & Disintegration IPEC opposed to inclusion of functionality in monographs but supportive of USP proposal for general chapters on Compactability, Lubrication & Disintegration Physical testing a necessary but insufficient guarantee of functionalities Physical testing a necessary but insufficient guarantee of functionalities Grade specificationGrade specification

Variable Raw Material + Fixed Process = Variable Product Raw Materials Process Product Control

Variable Raw Material + (Anti)variable Process = Constant Product Raw Materials Process Product Control (Anti-phase) PAT

Questions/Issues Holistic definition of Quality Holistic definition of Quality User/Supplier collaboration User/Supplier collaboration FDA 21 st century cGMP initiative (PAT) FDA 21 st century cGMP initiative (PAT) Functionality testing and specification Functionality testing and specification Sourcing higher specification materials Sourcing higher specification materials Tailored excipients Tailored excipients